Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12

Cancer Research

Volumn 69, Issue 15, 2009, Pages 6192-6199

  Zaharoff, David A ^a,b   Hoffman, Benjamin S ^a   Hooper, H Brooks ^a   Benjamin Jr , Compton J ^a   Khurana, Kiranpreet K ^a   Hance, Kenneth W ^a   Rogers, Connie J ^a   Pinto, Peter A ^a   Schlom, Jeffrey ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b 3202 Bell Engineering Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHITOSAN; CYTOKINE; PROTOSAN G 213; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERFICIAL CANCER; T LYMPHOCYTE; TH1 CELL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CHITOSAN; FEMALE; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-12; LUCIFERASES; MACROPHAGES; MICE; MICE, INBRED C57BL; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 68049147574     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1114     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008;26:341-345 (Pubitemid 351885380)
4. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-1694 (Pubitemid 29224536)
5. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183
6. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
7. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161:1124-1127 (Pubitemid 29426100)
8. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-368
9. Brunda MJ, Luistro L, Rumennik L, et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 1996;38 Suppl:S16-21.
10. Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-168
11. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-g production. J Immunol 1994;153:1697-1706
12. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-1403
13. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12- associated toxicity and interferon-g production. Blood 1997;90:2541-2548
14. Salem ML, Gillanders WE, Kadima AN, et al. Review: Novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res 2006;26: 593-608.
15. Egilmez NK, Kilinc MO, Gu T, Conway TF. Controlled- release particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune Disord Drug Targets 2007;7:266-270
16. O'Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol 2004;171:1330-1335 (Pubitemid 38327605)
17. Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 2005;66: 461-466 (Pubitemid 41138125)
18. Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 2003;26:343-348 (Pubitemid 36858718)
19. Di Martino A, Sittinger M, Risbud MV. Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. Biomaterials 2005;26:5983-5990 (Pubitemid 40805604)
20. Kumar MN, Muzzarelli RA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004;104:6017-6084
21. Read RC, Naylor SC, Potter CW, et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005; 23:4367-4374
22. McNeela EA, Jabbal-Gill I, Illum L, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004;22: 909-914 (Pubitemid 38221084)
23. Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999;182:21-32. (Pubitemid 29229791)
24. Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmstrom PU, Totterman TH. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim 2005;39:384-393 (Pubitemid 41565459)
25. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-g in response to bacillus Calmette- Guerin. J Immunol 1999;163:4246-4252 (Pubitemid 29474489)
26. Summerhayes IC, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro . J Natl Cancer Inst 1979;62:1017-1023
27. Jurczok A, Fornara P, Soling A. Bioluminescence imaging to monitor bladder cancer cell adhesion in vivo : a new approach to optimize a syngeneic, orthotopic, murine bladder cancer model. BJU Int 2008;101:120-124 (Pubitemid 350233560)
28. Gunther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999;59:2834-2837 (Pubitemid 29283119)
29. Saban MR, Simpson C, Davis C, et al. Discriminators of mouse bladder response to intravesical bacillus Calmette-Guerin (BCG). BMC Immunol 2007;8:6. (Pubitemid 46938935)
30. Riemensberger J, Bohle A, Brandau S. IFN-g and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002;127:20-26 (Pubitemid 34155453)
31. Arnold J, de Boer EC, O'Donnell MA, Bohle A, Brandau S. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-g. J Immunother 2004;27:116-123 (Pubitemid 38282731)
32. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150:1018-1023 (Pubitemid 23241327)
33. Gan YH, Zhang Y, Khoo HE, Esuvaranathan K. Antitumour immunity of bacillus Calmette-Guerin and interferon a in murine bladder cancer. Eur J Cancer 1999;35:1123-1129 (Pubitemid 29339197)
34. Yu S, Zhao Y, Wu F, et al. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm 2004;281:11-23. (Pubitemid 39024259)
35. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Muzzarelli C, Caramella C. Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. Eur J Pharm Sci 2004;21:351-359 (Pubitemid 38156173)
36. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release 2003;89:151-165
37. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 2005;57:1692-1712 (Pubitemid 41444256)
38. Kerec M, Bogataj M, Veranic P, Mrhar A. Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium. Eur J Pharm Sci 2005;25:113-121 (Pubitemid 40602201)
39. Grabnar I, Bogataj M, Mrhar A. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm 2003; 256:167-173 (Pubitemid 36412150)
40. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-969 (Pubitemid 36999613)
41. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003;63:2150-2157
42. Halak BK, Maguire HC, Jr., Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999;59:911-917
43. Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T. Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guerin immunotherapy. Int J Urol 2007;14:140-146 (Pubitemid 46121952)
44. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-586
45. O'Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK. The essential role of interferon-g during interleukin-12 therapy for murine transitional cell carcinoma of the bladder. J Urol 2004;171:1336-1342 (Pubitemid 38327606)
46. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T celldependent tumor rejection. Cancer Res 2002;62:5069-5075 (Pubitemid 34984436)
47. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo . J Immunol 2007;178:1357-1362 (Pubitemid 46154605)
48. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005;175:342-349 (Pubitemid 40884337)
49. Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res 1997;3:1661-1667 (Pubitemid 27431577)
50. Robertson MJ, Cameron C, Atkins MB, et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999;5:9-16. (Pubitemid 29045172)